company background image
LGP

Little Green PharmaASX:LGP Stock Report

Market Cap

AU$159.3m

7D

-4.9%

1Y

98.5%

Updated

26 Oct, 2021

Data

Company Financials +
LGP fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance3/6
Financial Health3/6
Dividends0/6

LGP Overview

Little Green Pharma Ltd engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for Little Green Pharma
Historical stock prices
Current Share PriceAU$0.68
52 Week HighAU$0.33
52 Week LowAU$1.02
Beta0
1 Month Change-3.57%
3 Month Change-18.18%
1 Year Change98.53%
3 Year Changen/a
5 Year Changen/a
Change since IPO92.86%

Recent News & Updates

Sep 06
Statutory Earnings May Not Be The Best Way To Understand Little Green Pharma's (ASX:LGP) True Position

Statutory Earnings May Not Be The Best Way To Understand Little Green Pharma's (ASX:LGP) True Position

After announcing healthy earnings, Little Green Pharma Ltd's ( ASX:LGP ) stock rose over the last week. While the...

Shareholder Returns

LGPAU PharmaceuticalsAU Market
7D-4.9%-1.0%0.8%
1Y98.5%8.7%24.4%

Return vs Industry: LGP exceeded the Australian Pharmaceuticals industry which returned 8.7% over the past year.

Return vs Market: LGP exceeded the Australian Market which returned 24.4% over the past year.

Price Volatility

Is LGP's price volatile compared to industry and market?
LGP volatility
LGP Beta0
Industry Beta1.3
Market Beta1

Stable Share Price: LGP is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: LGP's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016120Fleta Solomonhttps://www.littlegreenpharma.com

Little Green Pharma Ltd engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally. It offers cannabis flower products. The company was incorporated in 2016 and is headquartered in West Perth, Australia.

Little Green Pharma Fundamentals Summary

How do Little Green Pharma's earnings and revenue compare to its market cap?
LGP fundamental statistics
Market CapAU$159.26m
Earnings (TTM)AU$24.60m
Revenue (TTM)AU$7.00m

6.5x

P/E Ratio

22.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LGP income statement (TTM)
RevenueAU$7.00m
Cost of RevenueAU$1.23m
Gross ProfitAU$5.78m
Expenses-AU$18.83m
EarningsAU$24.60m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.10
Gross Margin82.47%
Net Profit Margin351.30%
Debt/Equity Ratio12.1%

How did LGP perform over the long term?

See historical performance and comparison

Valuation

Is Little Green Pharma undervalued compared to its fair value and its price relative to the market?

6.47x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate LGP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate LGP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: LGP is good value based on its PE Ratio (6.5x) compared to the Oceanic Pharmaceuticals industry average (44.9x).

PE vs Market: LGP is good value based on its PE Ratio (6.5x) compared to the Australian market (20x).


Price to Earnings Growth Ratio

PEG Ratio: LGP's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: LGP is good value based on its PB Ratio (1.7x) compared to the AU Pharmaceuticals industry average (3.7x).


Future Growth

How is Little Green Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-101.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LGP's earnings are forecast to decline over the next 3 years (-101.1% per year).

Earnings vs Market: LGP's earnings are forecast to decline over the next 3 years (-101.1% per year).

High Growth Earnings: LGP's earnings are forecast to decline over the next 3 years.

Revenue vs Market: LGP's revenue (61.1% per year) is forecast to grow faster than the Australian market (5.3% per year).

High Growth Revenue: LGP's revenue (61.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: LGP is forecast to be unprofitable in 3 years.


Past Performance

How has Little Green Pharma performed over the past 5 years?

40.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LGP has a high level of non-cash earnings.

Growing Profit Margin: LGP became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: LGP has become profitable over the past 5 years, growing earnings by 40.3% per year.

Accelerating Growth: LGP has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: LGP has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).


Return on Equity

High ROE: LGP's Return on Equity (26.2%) is considered high.


Financial Health

How is Little Green Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: LGP's short term assets (A$54.0M) exceed its short term liabilities (A$15.9M).

Long Term Liabilities: LGP's short term assets (A$54.0M) exceed its long term liabilities (A$1.2M).


Debt to Equity History and Analysis

Debt Level: LGP's debt to equity ratio (12.1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if LGP's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: LGP's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if LGP's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is Little Green Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LGP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LGP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LGP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LGP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LGP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average board tenure


CEO

Fleta Solomon

no data

Tenure

AU$971,093

Compensation

Ms. Fleta Jennifer Solomon serves as Managing Director at Little Green Pharma Ltd. She serves as Director of Little Green Pharma Ltd since May 29, 2017. She joins Little Green Pharma Ltd in February 2017....


CEO Compensation Analysis

Compensation vs Market: Fleta's total compensation ($USD728.88K) is above average for companies of similar size in the Australian market ($USD301.38K).

Compensation vs Earnings: Fleta's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: LGP's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 75.5%.


Top Shareholders

Company Information

Little Green Pharma Ltd's employee growth, exchange listings and data sources


Key Information

  • Name: Little Green Pharma Ltd
  • Ticker: LGP
  • Exchange: ASX
  • Founded: 2016
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$159.261m
  • Shares outstanding: 235.94m
  • Website: https://www.littlegreenpharma.com

Number of Employees


Location

  • Little Green Pharma Ltd
  • Level 2
  • Suite 2
  • West Perth
  • Western Australia
  • 6005
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/26 16:30
End of Day Share Price2021/10/26 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.